What is Allakos?
Founded in 2012 and headquartered in San Carlos, California, Allakos Inc. is dedicated to creating innovative treatments that target immunomodulatory receptors found on immune effector cells. The company's therapeutic approach aims to address a range of conditions including chronic spontaneous urticaria (CSU), with its lead candidate AK006 showing promise in early-stage studies. Allakos operates within the competitive biotechnology sector, focusing on unmet medical needs in immunology and inflammation.
How much funding has Allakos raised?
Allakos has raised a total of $276.4M across 3 funding rounds:
Series A
$42M
Series B
$100M
Stock Offering
$134.4M
Series A (2014): $42M with participation from RiverVest, Alta Partners, and Novo Ventures
Series B (2017): $100M led by Rock Springs Capital, LifeSci Venture Partners, New Enterprise Associates, 3x5 Partners, Redmile Group, Samsara BioCapital, Roche, RiverVest Venture Partners, Alta Partners, and Partner Fund Management
Stock Issuance/Offering (2018): $134.4M, investors not publicly disclosed
Key Investors in Allakos
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996. The firm focuses on innovative solutions that enhance patient outcomes and challenge existing healthcare paradigms.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California. New Enterprise Associates(NEA) is a venture capital firm focused on helping entrepreneurs build businesses.
What's next for Allakos?
The recent major strategic investment signals a pivotal moment for Allakos, likely enabling the company to accelerate its clinical development programs and potentially expand its research into new indications. This infusion of capital is crucial for navigating the complex and capital-intensive path of drug development, from late-stage clinical trials through regulatory approval and eventual commercialization. The company's focus on immunomodulatory receptors positions it to potentially disrupt current treatment paradigms in its target disease areas.
See full Allakos company page
